Recently, it has also been demonstrated that by using the CRISPR-Cas9, it is possible to correct the CFTR mutation in airway epithelial cells and patient-derived organoids, independently to which mutation the CF patient is bearing [86,87,88,89,90,91]. This evidence concerns the gene CFTR and cystic fibrosis.